Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
61
TERN Quote, Financials, Valuation and Earnings
Last price:
$27.15
Seasonality move
:
24.67%
Day range:
$26.53 - $28.17
52-week range:
$1.87 - $29.51
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
8.72x
Volume:
3.8M
Avg. volume:
4.5M
1-year change:
332.23%
Market cap:
$2.5B
Revenue:
--
EPS (TTM):
-$1.03
Analysts' Opinion
-
Consensus RatingTerns Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $30.44, Terns Pharmaceuticals, Inc. has an estimated upside of 10.75% from its current price of $27.49.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $17.00 representing 100% downside risk from its current price of $27.49.
Fair Value
-
According to the consensus of 9 analysts, Terns Pharmaceuticals, Inc. has 10.75% upside to fair value with a price target of $30.44 per share.
TERN vs. S&P 500
-
Over the past 5 trading days, Terns Pharmaceuticals, Inc. has underperformed the S&P 500 by -6.33% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Terns Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Terns Pharmaceuticals, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Terns Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Terns Pharmaceuticals, Inc. has grown year-over-year earnings for 5 quarters straight. In the most recent quarter Terns Pharmaceuticals, Inc. reported earnings per share of -$0.27.
Enterprise value:
2.2B
EV / Invested capital:
7.65x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-27.97x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$602K
Return On Assets:
-27.72%
Net Income Margin (TTM):
--
Return On Equity:
-29.05%
Return On Invested Capital:
-28.94%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$1.1M | -$902K | -$602K | -$206K | -$111K | |
| Operating Income | -$95.3M | -$100M | -$108.5M | -$24.9M | -$27.7M | |
| EBITDA | -$94.2M | -$99.1M | -$107.9M | -$24.7M | -$27.6M | |
| Diluted EPS | -$1.26 | -$1.18 | -$1.03 | -$0.28 | -$0.27 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $178.8M | $190.5M | $270.5M | $376.5M | $300.3M | |
| Total Assets | $179.9M | $192.6M | $271.7M | $378.2M | $301.7M | |
| Current Liabilities | $6.9M | $7.5M | $12.1M | $11.4M | $15.4M | |
| Total Liabilities | $7.7M | $8.9M | $13.3M | $13.8M | $17.6M | |
| Total Equity | $172.2M | $183.7M | $258.4M | $364.5M | $284.1M | |
| Total Debt | -- | $702K | $63K | $1M | $570K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$59.9M | -$74.8M | -$78M | -$16.5M | -$19.8M | |
| Cash From Investing | -$99.8M | $129.2M | -$42.4M | $31.8M | $24.5M | |
| Cash From Financing | $134.7M | $177.6M | $1M | $163.4M | -- | |
| Free Cash Flow | -$59.9M | -$74.9M | -$78M | -$16.5M | -$19.8M | |
TERN
Sector
Market Cap
$2.5B
$28.4M
Price % of 52-Week High
93.16%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-0.18%
-1.32%
1-Year Price Total Return
332.23%
-22.19%
Beta (5-Year)
--
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$27.67
200-day SMA
Buy
Level
$7.04
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$24.30
Relative Strength Index (RSI14)
Buy
Level
68.80
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-21.7907
50-day SMA
Buy
Level
$14.88
MACD (12, 26)
Buy
Level
3.97
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (14.6341)
Buy
CA Score
(Annual)
Level (0.1509)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (6.5608)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
Stock Forecast FAQ
In the current month, TERN has received 9 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TERN average analyst price target in the past 3 months is $30.44.
-
Where Will Terns Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Terns Pharmaceuticals, Inc. share price will rise to $30.44 per share over the next 12 months.
-
What Do Analysts Say About Terns Pharmaceuticals, Inc.?
Analysts are divided on their view about Terns Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Terns Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $17.00.
-
What Is Terns Pharmaceuticals, Inc.'s Price Target?
The price target for Terns Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $30.44 according to 9 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TERN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Terns Pharmaceuticals, Inc. is a Buy. 9 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TERN?
You can purchase shares of Terns Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Terns Pharmaceuticals, Inc. shares.
-
What Is The Terns Pharmaceuticals, Inc. Share Price Today?
Terns Pharmaceuticals, Inc. was last trading at $27.15 per share. This represents the most recent stock quote for Terns Pharmaceuticals, Inc.. Yesterday, Terns Pharmaceuticals, Inc. closed at $27.49 per share.
-
How To Buy Terns Pharmaceuticals, Inc. Stock Online?
In order to purchase Terns Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get TERN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TERN
Sector
P/E ratio
--
23.66x
PEG ratio
--
-0.01x
P/B ratio
8.72x
1.84x
Price / LTM sales
--
1.60x
Growth Metrics
TERN
Sector
Revenue growth
--
4.85%
Earnings growth
4.75%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.30
-$0.20
Profitability
TERN
Sector
Profitability FY 2024
-$896K
$3.6M
Return on invested capital
-28.94%
-30.98%
Return on assets
-27.72%
-27.62%
Return on equity
-29.05%
-36.69%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Mar
19
Estimated Next Earnings Date
Feb
9
Balance Sheet
TERN
Sector
Total cash
$295.6M
$27.2M
Short term investments
$196.7M
$25.7M
Total assets
$363.9M
$79.9M
Long term debt
$570K
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
